Home / Innere Medizin / Onkologie / ESMO 2018: „Die Daten der letzten drei Tage sind practice-changing“
OA Dr. Thamer Sliwa

ESMO 2018: „Die Daten der letzten drei Tage sind practice-changing“

OA Dr. Thamer Sliwa, Hanuschkrankenhaus Wien, berichtet wie die Studien aus den ersten zwei Presidential Symposien den klinischen Alltag verändern werden.

Quelle: ESMO 2018 Congress

Schmid P et al., IMpassion130: Results from a global, randomised, double-blind, phase 3 study of atezolizumab (atezo) + nab-paclitaxel (nab-P) vs placebo + nab-P in treatment-naive, locally advanced or metastatic triplenegative breast cancer (mTNBC); LBA1 PR

Cristofanilli M et al., Overall survival (OS) with palbociclib plus fulvestrant in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer (ABC): Analyses from PALOMA-3; LBA2 PR

Parker CC et al., Radiotherapy (RT) to the primary tumour for men with newly-diagnosed metastatic prostate cancer (PCa): Survival results from STAMPEDE (NCT00268476); LBA5_PR

Motzer RJ et al., JAVELIN Renal 101: A randomized, phase III study of avelumab + axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma (aRCC). ESMO 2018 Kongress, LBA6_PR

LOGIN

Login

Passwort vergessen?